DESTINY Breast Respond HER2-(Ultra)Low Europe

Clinical trial NCT05945732 · RECRUITING

Trial details

NCT number: NCT05945732
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Status: RECRUITING
Study type: OBSERVATIONAL

Unresectable Breast Cancer Metastatic Breast Cancer HER2-low Expressing Breast Cancer HER2-(Ultra)Low Expressing Breast Cancer

Start date: 2023-10-24
Primary completion: 2030-12-31
Enrollment: 2295

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.